Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Expert Report on advances in the management of HER2-negative and HER2-low advanced breast cancer from ASCO 2022

Reporting from ASCO 2022 Annual Meeting in Chicago, Nadia Harbeck discusses the practice changing results from DESTINY-Breast04 testing trastuzumab deruxtecan vs physician's choice of treatment in HER2-low metastatic Breast Cancer, including safety profile data. She also comments the interesting results from the TROPiCS-02 trial testing sacituzumab govitecan vs physician's choice of treatment in HR-positive/HER2-negative pre-treated advanced Breast Cancer.

This video was supported with an unrestricted grant from Bayer Healthcare.
The selection of study results covered in this track is exclusively under the responsibility of ESMO and the speakers selected by ESMO.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.